Boehringer Ingelheim Gains China NMPA Conditional Approval for Zongertinib in First-Line HER2-Mutant NSCLC

Conditional approval from China's National Medical Products Administration (NMPA) for zongertinib tablets (HERNEXEOS) as a first-line monotherapy in HER2 (ERBB2)-mutant advanced NSCLC signals that Boehringer Ingelheim is now managing parallel post-approval obligations across two major regulatory jurisdictions simultaneously, a supply-chain and quality-system pressure point that plant heads and QA directors should be tracking closely.

The NMPA decision, issued in May 2026, covers adult patients with unresectable, locally advanced or metastatic NSCLC harboring activating HER2 tyrosine kinase domain mutations who have not received prior systemic therapy. It follows the U.S. FDA accelerated approval granted in February 2026 under a comparable expedited pathway, creating a dual confirmatory-trial obligation: full approval in both markets remains contingent on verification of clinical benefit in ongoing studies. China's CDE had previously granted Breakthrough Therapy Designation for the first-line indication, consistent with the regulatory urgency framing applied in the U.S.

The approval package rests on a treatment-naïve cohort of 74 patients from the Phase Ib Beamion LUNG-1 trial, which reported a 75.7% objective response rate, 10.8% complete response, 64.9% partial response, and a median duration of response of 15.2 months. These data were simultaneously published in The New England Journal of Medicine and presented at ELCC 2026. In the broader pooled safety population of 177 HER2-mutant NSCLC patients, dose reductions occurred in 9% of patients and discontinuations in 6%, with treatment-related adverse events described as predominantly low-grade.

For regulatory affairs leads, the conditional approval structure under NMPA mirrors the confirmatory-evidence requirements familiar from 21 CFR Part 314 Subpart H accelerated approval mechanics: commercial supply must be GMP-compliant and inspection-ready while post-marketing commitments run concurrently. The therapy is also approved in China for previously treated patients, meaning the commercial presentation must support both lines of therapy under a single regulatory dossier, a labeling and change-control consideration for quality teams managing the China registration file.

Lung cancer accounts for the highest cancer mortality in China, with incidence and mortality rates rising in recent years; HER2 mutations account for up to 4% of NSCLC cases globally, defining a molecularly selected but commercially meaningful patient population that will require companion diagnostic alignment across both markets.

The confirmatory trial readout will determine whether conditional status converts to full approval in China, setting a measurable milestone against which manufacturing scale-up and distribution commitments will ultimately be assessed.

Source: Boehringer Ingelheim via GlobeNewswire, 22 May 2026.